EN

EN

CN

  • R&D Technology Platform

    1. AAV Vector Modification and Screening

      Through rational design and in vitro/in vivo screening platform, we have developed novel rAAV capsid variants of various serotypes with strong tissue targeting, high induction efficiency, and low immunogenicity.
      We have also optimized recombinant baculovirus virus design to produce high quality AAV vectors in Sf9 cells.

    2. Gene Expression Cassette Optimization

      Through optimizing rAAV vector and GOI sequences, we have improved target protein expression level, enhanced tissue specificity of gene expression while reducing immunogenicity.

    More

  • Production Technology Platform

    1. Based on the Sf9 insect cell expression system, we have established rAAV GMP production platform with large-scale capacity, high yields and low costs.

    2. With an optimized purification process, we have controlled empty capsid levels less than 5%, significantly enhancing product safety, setting a strong competitive advantage.

    3. Established a full-spectrum AAV quality control and assurance system that meets the regulatory standards across the United States, European Union, and China for gene therapy products.

    More
TA Product Indication Research IND Enabling Clinical Stage Regulatory
Designation
Phase 1 Phase 2 Phase 3
OPHTHALMOLOGY FT-001 LCA2
FT-002 XLRP
FDA ODD
FDA Fast Track
FT-003 nAMD
DME
DR
HEMATOLOGY FT-004 Hemophilia B
FT-005 Hemophilia A
CARDIOLOGY FT-017 HCM
FT-018 ARVC

Together with Us
To Build Health and the Future

Contact Us

Boston R&D Center：+1 617-5467300Shanghai Operation Center：+86 21-58206061Suzhou Manufacturing Site：+86 512-85883110

Legal Notice Copyright © 2025 Frontera Therapeutics, Inc. 沪公网安备31011502401398号 Powered by Xinhongru